贝赛尔特公司概况

Current Qosition:

Home >  Successful case

Successful case

The team has cooperated with the Institute Of Hematology, Peking University People's Hospital since 2016 and together we successfully cured a 3-year-old patient with relapsed refractory acute lymphoblastic leukemia (ALL) by using pioneering HLA-haploidentical allogeneic CAR-T cell therapy (T-cells of the patient's relatives). At present, the patient recovered without relapse for three years and four months. This is the only successful case of its kind in the world. Therefore this clinical approach, by the industry, is also known as allogeneic CAR-T immunotherapy “Beijing Approach”. It finds a new way for applying haploidentical allogeneic CAR-T cell therapy to the patients who cannot accept autologous CAR-T cell treatments. This gives all relevant patients who have leukemia an opportunity to get the CAR-T therapy and makes China to be the leading country in the field of allogeneic CAR-T technology.

At the moment, the state gradually opens-up the policy of cell and gene therapy and the company has received new financing for further expanding its R&D department. It forms a technical and management team which is responsible for the research and development, production and quality control, clinical trials operation management, new drugs innovation and registration of the cell-based gene therapy and immunotherapy. To plan and build a cell production workshop that complies with the international CGMP standards and to establish wholly owned subsidiaries in the United States.

The company's senior technical team is trying to develop a new immune cell technology and products with independent intellectual property rights. The team is devoting its attention to use different methods of immunotherapy to improve the effectiveness of the treatment, survival rate and the quality of life of the Chinese cancer patients. More patients can be benefit from scientific progress. The company will use its profound academic background to cooperate with well-known scientific research institutions and medical units in the wolrd (already work with the University of Pennsylvania, the Duke University, the Peking University Medical department, the Peking University Third hospital and the Translational Hepatology Institute of the Capital Medical University (THI-CMU)). Together, to build a national immune cell engineering research centre and precision medicine transformation application platform. To develop the the third class of drugs, which are living cell treatments, rather than chemical drugs and monoclonal antibodies. Bioceltech has the ambition to become the international leading national enterprise in this new therapeutic area.